(Reuters) - Vertex Pharmaceuticals Inc's <VRTX.O> new cystic fibrosis drug Kalydeco, when combined with its experimental treatment for the disease, led to significantly improved breathing ability in a mid-stage study, sending Vertex shares soaring 49 percent.
(Reuters) - Vertex Pharmaceuticals Inc's <VRTX.O> new cystic fibrosis drug Kalydeco, when combined with its experimental treatment for the disease, led to significant improvement in lung function in a mid-stage study, sending Vertex shares soaring 45 percent.
Shares of Vertex Pharmaceuticals Inc. soared nearly 50 percent in pre-market trading Monday after the drug developer said it saw better-than-expected results in a mid-stage study of a potential treatment for the most severe form of cystic fibrosis.
(Reuters) - Vertex Pharmaceuticals Inc's <VRTX.O> new cystic fibrosis drug Kalydeco, when combined with its experimental treatment for the disease led to significant improvement in lung function in a mid-stage study, sending Vertex shares soaring 57 percent.
Gilead Sciences shares soared more than 15 percent after an experimental hepatitis C drug acquired by the company when it paid nearly $11 billion to buy Pharmasset produced encouraging results in a closely watched clinical trial, results of which were released in Barcelona.
Gilead Sciences said some patients treated with its experimental hepatitis C drug, which the company acquired with its $11 billion buy of Pharmasset, experienced a relapse of the infection in an ongoing study.
Vertex Pharmaceuticals is expected to report strong initial sales of its cystic fibrosis drug Kalydeco on Thursday as investors shift their attention away from the waning performance of the company's hepatitis C drug Incivek... Read More
Every quarter hedge funds and large investors file their holdings with the SEC, revealing value picks, cyclical bets, growth opportunities and activist pushes... Read More
Investors are riding a wave of unprecedented optimism following what seems like an avalanche of biotech deals, early drug approvals, and positive clinical news that has kicked off the year... Read More